Company Information
CIN
Status
Date of Incorporation
01 December 1984
State / ROC
HimachalPradesh / ROC Himachal Pradesh
Last Balance Sheet
31 March 2023
Last Annual Meeting
28 September 2023
Paid Up Capital
1,022,271,416
Authorised Capital
2,500,000,000
Directors
Praveen Kumar Dutt
Director/Designated Partner
over 2 years ago
over 2 years ago
Manoj Joshi
Director/Designated Partner
over 2 years ago
over 2 years ago
Ajay Kumar Sharma
Director/Designated Partner
over 2 years ago
over 2 years ago
Sanjay Suri
Director/Designated Partner
over 2 years ago
over 2 years ago
Sushil Suri
Director/Designated Partner
over 2 years ago
over 2 years ago
Anju Suri
Director/Designated Partner
over 2 years ago
over 2 years ago
. Savita
Director/Designated Partner
about 5 years ago
about 5 years ago
Vipul Kumar Srivastava
Company Secretary
about 7 years ago
about 7 years ago
Sukhcharan Singh
Director/Designated Partner
over 20 years ago
over 20 years ago
Bhupender Raj Wadhwa
Director/Designated Partner
over 20 years ago
over 20 years ago
Past Directors
Archana Bhargava
Additional Director
about 10 years ago
about 10 years ago
Arun Kumar Sinha
Whole Time Director
over 20 years ago
over 20 years ago
Patents
This invention describes a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resulting in statins particularly simvastatin with purity greater than 99% and dimer ...
The invention describes novel Atorvastatin Polymorphs designated as M-2, M-3 and M-4 having substantially different XRD from those of the reported Forms and processes for the preparation thereof The process comprises crystallizing the desired form using atorvastatin in solid or liquid form, ecologically friendly sol...
The invention relates to 'Method of preparing Garlic Ointment and Garlic-Ointment composition' for external use on infected skin.
An antibacterial gel composition comprising cotrimoxazole comprising trimethoprim and mu 1 tamethoxazol in the rario 1:5 avid Sodium metapisulphite 0.05 to 0.5 % by w/w.
The present invention relates to new polymorph of Linagliptin along with novel processes for various polymorphs of Linagliptin. It also reports an improved process for preparation of highly pure Linagliptin.
The present invention relates to a nutritional supplement comprising docosahexaenoic acid (DHA), Vitamin A, Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin B12, Folic Acid, Vitamin C, Vitamin D3 and Vitamin E, Zinc, Choline, Iodine, Selenium, Glutamine and L-Lysine. Also disclosed is the method f...
The present invention relates to new polymorphic forms of Crystalline Rosuvastatin calcium along with novel processes for crystalline as well as amorphous Rosuvastatin calcium.
The present invention relates to the improved processes for the purification of Loratadine
intermediate 1 l-(N-methyl-4-piperidinylidine)-8-chloro-6,l l-dihydro-5H-benzo(5,6)cyclohepta
• (1,2-b) pyridine (compound of formula I) so as reduce / remove the impurity ll-(N-Methyl-4-
piperidinyl)-ll-Fluoro-8-chloro-6,l...
The present invention relates to novel process for Sitagliptin phosphate which results in removal of 3-amino-4-(2,4,5-trifluorophenyl)butanoic acid impurity (Amino-TFPBA).
The present invention relates to a novel Fexofenadine amine salts intermediates of formula III. The present invention also describes the improved process for highly pure Fexofenadine hydrochloride & its intermediates of formula II & IV, as well as a single analytical method for HPLC analysis of Fexofenadine Hydrochl...
The present invention relates to various improved processes of Candesartan Cilexetil for control as well as removal of various critical impurities like Candesartan acid, Desethyl Candesartan Cilexetil which are formed during synthesis of Candesartan Cilexetil.
The present invention relates to the novel processes for the preparation of Anhydrous crystalline Sitagliptin phosphate.
Fig. 1
An improved process for the production of Desloratadine is described wherein Loratadine is reacted with neat alcohol in presence of inorganic base, followed by isolating Desloratadine on addition of excess water in crystalline form.
The present invention describes the preparation of highly pure (i.e. falling in ICH quality parameters with respect to related substances) stable amorphous Atorvastatin calcium salt comprising (a) hydrolysis of 1,3-dioxane ring of (4R-cis)-l,l-dimethylethyl-6-[2-[2-(4-fluorophenyl)-5-(1 -methylethyl)-3-phenyl-4-[(ph...
New amine salts of Atorvastatin, process for their preparation and their use in the preparation of highly pure i.e. almost impurity free amorphous as well as crystalline Atorvastatin hemi calcium salt in high yields.
This invention provides crystalline polymorphic form 2 of VD 1827 tosylate characterized by the following infra red spectrum pattern:
2978,1793, 1689, 1498, 1459,1326,1175,1126,1009, 975, 684, 570 (± 5 cm-1) The invention is further characterized by the following XRD pattern expressed in terms of "2 Theta" and "d" ...
The invention describes a novel polymorph of montelukast sodium that is more pure in terms of residual solvent and less moisture sensitive. The new polymorph is characterized by unique X-ray diffraction peak at 20= 21.14(99%). The invention also provides a process for preparing said polymorph by converting monteluka...
A process for the production of loratadine chemically known as 8-chioro- 11 -(1-ethoxycarbonyl-4-piperidylidene)-6, 11 -dihydro-5H-benzo[5 ,6]cyclohepta[ 1 ,2-blpyridene has been described. The process comprises reacting a tn-cyclic aromatic ketone with an organometallic compound containing Mg in presence of organic...
The present invention provides an improved process for manufacturing statins comprising the following steps (i) reacting lovastatin with butyl amine to produce lovastatin amide (ii) isolating lovastatin butylamide in solid form by crystallization, from organic solvent (iii) optionally sunjecting to hydroxyl protecti...
The invention discloses two new polymorphs of Fexofenadine hydrochloride and a process preparing the same. The forms are designated by us as IXX and XX. The forms are prepared by contacting fexofenadine base with hydrogen chloride gas in presence of organic solvent followed by crystallization.
The present invention provides process for preparation of MonteiUKast acia (L) ana salt thereof (II) which comprises reacting the compound of formula (III) with methane sulphonyl chloride and reacting the resultant mesylate of formula (IV) with l-(mercaptomethyl) cyclopropane derivatives of formula (Xa/ Xc/ Xd) in a...
The present invention relates to the purification process of Loratadine using ethyl acetate which is cost effective and results in highly pure. i.e. almost impurity free Loratadine polymorphic form I, as confirmed by its XRD, IR & Melting range.
Atorvastatin calcium Form VI Or hydrates thereof, characterized by its X−ray powder diffraction and/or solid state NMR is described, as well as methods for the preparation of the same.
The invention describes an effective process for manufacturing a key intermediate of Ramipril named as (S,S,S)-2-azobicyclo [3,3,0] octane-3-carboxylic acid benzyl ester hydrochloride [(S,S,S)-enantiomer)] by resolution of its racemate. The separation of diastereomeric mixture of key intermediate, (S,S,S)- enantiome...
An Improved Method For The Preparation Of Montelukast Acid And Sodium Salt Thereof In Amorphous Form
A method for the preparation of montelukast acid sodium salt thereof in amorphous form has been described. The method comprises of following steps:
(a)generating the dilithium dianion of 1-(mercaptomethyl)cyclopropane acetic acid, by reacting with alkyl lithium,
(b)coupling the said dianion with wet mesylate to ge...
The process comprises (i) subjecting substituted benzyl halide to cyanation in a biphasic system using water immiscible solvents by any known methods, (ii) condensing in situ the phenyl acetonitrile thus obtained with nicotinic ester in presence of alkali metal alkoxide and water immiscible organic solvent to produc...
The present invention relates to new salts (II) of Montelukast (I) and process for preparing these salts. where B is ammonia, benzylamine or phenyl hydrazine. The invention also provides a process for preparation amine salts comprising (a) dissolving/ suspending the Montelukast free acid of formula (I) in an organic...
The present invention relates to new polymorphic form of Crystalline Rosuvastatin calcium along with novel processes for crystalline as well as amorphous Rosuvastatin calcium.
The present invention relates to the novel processes for the preparation of various polymorphic
forms of Aliskiren Hemifumarate.
The present invention relates to the improved processes for the preparation as well as purification
of atorvastatin calcium and its intermediate so as reduce 1 remove the critical impurities below
the specified limit / desired level. The resulting Atorvastatin calcium or its intermediate can be
used further for t...
An improved process for the synthesis of palmidrol
The process of this invention comprises preparing anhydride of palmitic acid and alkyl or cycloalkyl haloformate by any conventional method, reacting anhydride so formed with ethnolamine in-situ, and isolating the product by any known methods such as solvent recove...
The present invention relates to the novel industrially applicable & cost effective purification processes for highly pure & stable white Desloratadine.
The present invention relates to the novel industrially applicable & cost effective processes for
the preparation of pure Rosuvastatin calcium & intermediates thereof almost free from
Rosuvastatin calcium anti-isomer.
A process comprising addition of half equivalent of powdered sodium hydroxide to valproic acid at 10-60°C, and then adding acetone or acetonitrile to obtain a clear solution, followed by cooling to 5-20°C and isolating the title compound by conventional methods. A still another option, is heating equimolar mixture o...
The present invention relates to the new polymorphic forms of Sitagliptin Phosphate and
processes thereof.
The invention provides a process for preparing derivatives of thiozolidinediones and their precursors comprising,
(a) reacting a compound of general formula I wherein ri, R2 and R3 may be same or
different and represent H, alkyl or alkoxy with C varying from 1 to 6, halogens, mono or di-substituted alkyl and aryl ...
The present invention provides a more simplified, cost effective, commercially feasible process for the manufacture of Carvedilol (I) comprising a step of reacting 4-hydroxy carbazole (II) with epichlorohydrin and directly isolating the intermediate 4-(2,3-epoxypropoxy) carbazole (III) which on purification followed...
The present invention relates to new polymorphic form of Crystalline Rosuvastatin calcium and novel processes for their preparation.
AN IMPROVED PROCESS FOR THE SYNTHESIS OF HIGHLY PURE LINAGLIPTIN ALONG WITH NEW POLYMORPH & NOVEL PROCESSES FOR PREPARATION OF VARIOUS POLYMORPHS OF LINAGLIPTIN
ABSTRACT
The present invention relates to new polymorph of Linagliptin along with novel processes for various polymorphs of Linagliptin. It also reports a...
AN IMPROVED PROCESS FOR THE SYNTHESIS OF HIGHLY PURE LINAGLIPTIN ALONG WITH NEW POLYMORPH & NOVEL PROCESSES FOR PREPARATION OF VARIOUS POLYMORPHS OF LINAGLIPTIN
ABSTRACT
The present invention relates to new polymorph of Linagliptin along with novel processes for various polymorphs of Linagliptin. It also reports a...
The.present invention relates to a nutraceutical composition comprising, Vitamin C, Hawthorn
Berry, Beetroot, L- Citruline, Sodium Nitrite Methylcobalamin, CO Q 10, Calcium Carbonate
and Vitamin 03 in an oral disintegrating tablet form and its method for preparing the same. The
Nutraceutical tablet is meant to in...
The present invention relates to a nutraceutical composition comprising, Vitamin C, Hawthorn
Berry, Beetroot, L-. Citruline, Sodium Nitrite Methylcobalamin and CO Q 10, in an oral
disintegrating tablet form and its method for preparing the same. The Nutraceutical tablet is
meant to increase or Restore Nitric oxid...
The present invention relates to the novel processes for preparation of crystalline Empagliflozin.
Fig. 1
The present invention relates to various novel processes for the preparation of Crystalline Form SC-3 of Dapagliflozin Propanediol Monohydrate.
Fig. 1
The present invention relates to a new polymorphic form of Canagliflozin designated as polymorphic Form M along with novel processes for its preparation.
Fig. 1
The present invention relates to Novel amine salts & amide derivatives of various Acid
drugs, mainly, Atorvastatin, Montelukast, Fexofenadine, Rosuvastatin, Simvastatin,
Lovastatin, Ursodiol, Acefyllinate, Repeglinide, Furosemide, Telmisartan, Valsartan,
Diclofenac, Ibuprofen, Indomethacin & Acetyl salicyclic aci...
The present invention relates to the novel processes for preparation of Polymorphic Form A of Rupatadine.
The present invention relates to ? stable pharmaceutical composition in form of aqueous syrup comprising Desloratadine and Montelukast Sodium, which is essentially free of sugar. The present invention provides a stable pharmaceutical composition in form of aqueous syrup for oral administration comprising Desloratadi...
The present invention relates to the improved processes for preparation of
Loratadine intermediate 11 -(N-methyl-4-piperidinylidine)-8-chloro-6,11 -dihydro-
5H-benzo(5,6)cyclohepta (1,2-b) pyridine (compound of Formula I) so as reduce /
remove 1 l-(N-Methyl-4-piperidinyl)-l l-hydroxy-8-chloro-6, 1 l-dihydro-5H-
...
The present invention relates to the novel processes for preparation of crystalline Empagliflozin.
The present invention reports novel purification processes for Chenodeoxycholic Acid (CDCA), 7-Ketolithocholic acid (KLCA as well as Ursodeoxycholic acid (UDCA). Furthermore, the present invention also reports process for the preparation as well as purification of Silyl- Ursodeoxycholic acid (Silyl-UDCA).
...
The present invention relates to the new acid salts of Sitagliptin i.e. Sitagliptin Benzoate & Sitagliptin Oxalate, novel processes for their preparation and new polymorphs of Anhydrous Sitagliptin phosphate. Besides these, this invention also provides a novel process for the preparation of Sitagliptin Phosphate Mon...
The present invention relates to the novel processes for preparation & purification of Rivaroxaban & its various intermediates.
The present invention relates to the novel processes for purification of Apixaban & processes for the preparation thereof.
The present invention relates to the novel processes for preparation of crystalline Empagliflozin.
The present invention reports Improved Process for the preparation of Ertugliflozin L-Pyroglutamate and its Intermediates.
The present invention reports New Amine salts of Febuxostat and Novel processes thereof. Furthermore, New amine salts of Febuxostat of high purity are obtained in high yield and results highly pure Febuxostat which otherwise is very difficult to achieve without significant yield loss.
ABSTRACT
IMPROVED PROCESS FOR THE PREPARATION OF VILDAGLIPTIN
Improved process for the preparation of Vildagliptin is disclosed to control the Vildagliptin Dimer impurity. Furthermore, improved, cost-effective and commercially feasible processes for the preparation of intermediates of Vildagliptin are also disclos...
The present invention provides a process for preparation of polymorphic Form H3 of Apixaban. Apixaban is useful as a direct inhibitor of activated factor (FXa) in the treatment of thromboembolic diseases.
The present invention relates to an improved process for preparation of highly pure Linagliptin which ensures the removal of Linagliptin Dimer impurity. It includes preparation of Linagliptin as per prior art and its purification by its benzoate or mandelate salt formation or by treatment with Methanesulphonic acid,...
An improved process for the preparation of amorphous atorvastatin calcium, salt (2:1) is prepared by (a) optionally hydrolysing the lactone form of atorvastatin in solution form with aqueous solution of alkali or alkaline earth metal hydroxide till disappearance of the said lactone, (b) extracting the said h...
The present invention reports improved processes for the preparation as well as purification of Vortioxetine Hydrobromide and its intermediates.
NOVEL PROCESSES FOR THE PREPARATION OF AMORPHOUS APIXABAN
ABSTRACT
The present invention relates to the novel processes for preparation of Amorphous Apixaban.
Fig. 01
The present invention relates new polymorphs of Linagliptin designated as Form M1, M2 & M3 and novel processes thereof and Forms XXII & C.
The present invention reports improved process for the preparation of Edoxaban Tosylate and its intermediates.
The present invention relates to a novel Fexofenadine amine salts intermediates of formula III & IIIa. The present invention also describes the improved process for highly pure Fexofenadine hydrochloride & its intermediates of formula II & IV, as well as a single analytical method for HPLC analysis of Fexofenadine...
The present invention relates to the novel processes for preparation of amorphous Edoxaban Tosylate
NEW POLYMORPHIC FORM OF VORTIOXETINE HYDROBROMIDE & NOVEL PROCESSES THEREOF
ABSTRACT
The present invention relates to a new polymorphic form of Vortioxetine Hydrobromide & Novel Processes for its preparation using spray drier technique.
NOVEL PROCESSES FOR THE PREPARATION OF AMORPHOUS
LINAGLIPTIN
ABSTRACT
The present invention relates to the novel processes for preparation of amorphous Linagliptin.
Fig. 01
NOVEL PROCESSES FOR THE PREPARATION OF AMORPHOUS
EMPAGLIFLOZIN
ABSTRACT
The present invention relates to a novel processes for preparation of Amorphous
Empagliflozin.
Fig. 01
The present invention relates to an improved process for preparation of highly pure Vonoprazan fumarate by using purified intermediates. Particularly, this present invention provides improved process for preparation of 5-(2-Fluorophenyl)-l-(pyridine-3-ylsulphonyl)-l-H-pyrrole-3-carbaldehyde, a key intermediate.
...
AN IMPROVED, ECO-FRIENDLY & COMMERCIALLY VIABLE PROCESS FOR THE PREPARATION OF A KEY INTERMEDIATE OF ATORVASTATIN CALCIUM.
ABSTRACT:
The present invention generally relates to an improved, eco-friendly and economical process for the preparation of Highly pure Key Atorvastatin Intermediate (4R-cis)-l,l-dimeth...
The present invention reports high purity novel amine salts of Saroghtazar & Novel Methods of preparation thereof. It also reports improved processes for preparation of Amorphous Saroghtazar magnesium by making use of spray drying and other technique.
Figure: 01
IMPROVED PROCESSES FOR THE PREPARATION AS WELL AS PURIFICATION OF BREXPIPRAZOLE AND ACID SALTS THEREOF
ABSTRACT
The present invention reports “Improved Processes for the preparation as well as purification of Brexpiprazole & its Acid salt.
The present invention relates to a process for the purification of saxagliptin monohydrate wherein each impurity specifically corresponding amide impurity or cyclic amidine impurity has been controlled in an amount less than 0.1% or less than 0.05%w/wbyHPLC.
ABSTRACT
The present invention relates to Novel amine salts & amide derivatives of various Acid drugs, mainly, Atorvastatin, Montelukast, Fexofenadine, Rosuvastatin, Simvastatin, Lovastatin, Ursodiol, Acefyllinate, Repeglinide, Furosemide, Telmisartan, Valsartan, Diclofenac, Ibuprofen, Indomethacin & Acetyl salic...
ABSTRACT
The present invention relates to Novel amine salts & amide derivatives of various Acid drugs, mainly, Atorvastatin, Montelukast, Fexofenadine, Rosuvastatin, Simvastatin, Lovastatin, Ursodiol, Acefyllinate, Repeglinide, Furosemide, Telmisartan, Valsartan, Diclofenac, Ibuprofen, Indomethacin & Acetyl sal...
ABSTRACT
The present invention relates to an improved process for the manufacture of Form M2 of linagliptin.
Fig. 02
N
ABSTRACT
The present invention relates new polymorphs of Linagliptin designated as Form M1, M2 & M3 and novel processes thereof and Forms XXII & C.
Fig. 01
ABSTRACT
AN IMPROVED PROCESS FOR THE PREPARATION OF TAFAMIDIS FORM 1
The present invention provides an improved and efficient process for preparation of tafamidis form 1 in consistent manner and which is free from other polymorphic forms.
PROCESS FOR THE PREPARATION OF HIGHLY PURE AMORPHOUS TELMISARTAN SODIUM
The present invention is related to highly pure amorphous telmisartan sodium of formula I and processes for preparation thereof.
Formula I
ABSTRACT
The present invention relates to a stable pharmaceutical composition of empagliflozin or its pharmaceutically acceptable salts, solvates thereof along with one or more pharmaceutically acceptable excipients. More specifically, the present invention relates to a process of preparing a stable pharmaceutica...
NOVEL CRYSTALLINE POLYMORPHIC FORMS OF TAFAMIDIS AND PROCESSES FOR PREPARATION THEREOF
The present invention relates to novel crystalline polymorphic forms of tafamidis and processes for their preparation.
ABSTRACT
The present invention relates to various novel processes for the preparation of Crystalline Form SC-3 of Dapagliflozin Propanediol Monohydrate.
Fig. 1
ABSTRACT
The present invention relates to the new acid salts of Sitagliptin i.e. Sitagliptin Benzoate & Sitagliptin Oxalate, novel processes for their preparation and new polymorphs of Anhydrous Sitagliptin phosphate. Besides these, this invention also provides a novel process for the preparation of Sitagliptin P...
ABSTRACT
The present invention relates to the new acid salts of Sitagliptin i.e. Sitagliptin Benzoate & Sitagliptin Oxalate, novel processes for their preparation and new polymorphs of Anhydrous Sitagliptin phosphate. Besides these, this invention also provides a novel process for the preparation of Sitagliptin P...
ABSTRACT
The present invention relates to the new acid salts of Sitagliptin i.e. Sitagliptin Benzoate & Sitagliptin Oxalate, novel processes for their preparation and new polymorphs of Anhydrous Sitagliptin phosphate. Besides these, this invention also provides a novel process for the preparation of Sitagliptin P...
The present invention relates to an improved and industrially advantageous process for the purification of bempedoic acid. More specifically, the present invention provides a process for the purification of bempedoic acid wherein the individual impurities are controlled as per ICH guidelines to obtain pure bempedo...
The present invention relates to an improved process for the preparation of tofacitinib and its pharmaceutically acceptable salt thereof, wherein the process minimizes the possibilities of by-products formation.
ABSTRACT
The present invention relates to an improved process for the preparation of pure nintedanib and conversion to its pharmaceutically acceptable salts. More particularly, the present invention provides an efficient process for purification of nintedanib, substantially free from impurities.
...
A process for the preparation of a solid, orally administrable pharmaceutical composition, comprising rivaroxaban and other pharmaceutically acceptable excipients. More specifically, the composition comprises of preparing inert granules devoid of active compound.
The present invention relates to an improved process for the preparation of vortioxetine and its pharmaceutically acceptable salts. More particularly, the present invention relates to a preparation and purification process of vortioxetine hydrobromide substantially free from impurities.
The present invention relates to an industrially advantageous process for the purification of rivaroxaban intermediate, specifically rivaroxaban amino intermediate. More specifically, the present invention provides rivaroxaban with high chemical and enantiomeric purity by using pure rivaroxaban amino intermediat...
ABSTRACT
The present invention reports novel purification processes for Chenodeoxycholic Acid (CDCA), 7-Ketolithocholic acid (KLCA as well as Ursodeoxycholic acid (UDCA). Furthermore, the present invention also reports process for the preparation as well as purification of SilylUrsodeoxycholic acid (Silyl-UDCA)...
ABSTRACT
The present invention reports novel purification processes for Chenodeoxycholic Acid (CDCA), 7-Ketolithocholic acid (KLCA as well as Ursodeoxycholic acid (UDCA). Furthermore, the present invention also reports process for the preparation as well as purification of SilylUrsodeoxycholic acid (Silyl-UDCA)...
ABSTRACT
The present invention reports novel purification processes for Chenodeoxycholic Acid (CDCA), 7-Ketolithocholic acid (KLCA as well as Ursodeoxycholic acid (UDCA). Furthermore, the present invention also reports process for the preparation as well as purification of SilylUrsodeoxycholic acid (Silyl-UDCA)...
The present invention relates to a pharmaceutical composition of edoxaban tosylate which is devoid of sugar alcohol. Further, the present invention relates to a process for the preparation of pharmaceutical composition of edoxaban tosylate.
The present invention relates to a process for the purification of ticagrelor. More specifically, the present invention relates to an efficient process for the purification of ticagrelor which substantially eliminates the potential impurities formed during the course of reaction.
The present invention relates to an efficient process for the purification of bilastine. More specifically, the present invention relates to a consistently reproducible and industrially advantageous process for the purification of bilastine, wherein level of all impurities has been controlled as per ICH guidelines.
...
The present invention relates to an industrially advantageous process for the preparation of bilastine methyl ester. More specifically, the present invention relates to a process for the preparation of pure bilastine methyl ester intermediate and its conversion into bilastine.
The present invention relates to an improved process for the preparation of vortioxetine hydrobromide ß form. More particularly, the present invention relates to a reproducible process for consistently obtaining crystalline vortioxetine hydrobromide ß form at industrial scale.
The present invention relates to an industrially advantageous process for the preparation of pyridazinone derivative. More specifically, the present invention relates to an efficient process which is operationally simple and suitable for industrial application and will eliminate or limit the presence of impurities i...
The present invention relates to an efficient process for the purification of substituted pyridazinone intermediate. More specifically, the present invention relates to a purification method of ethyl(Z)-(2-cyano-2-(2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)hydrazineylidene)acetyl)car...
Registered Trademarks
[Class : 35] Advertising, Marketing, Business Management, Business Administration And Office Functions
[Class : 38] Chartroom Services For Social Networking, Forums [Chat Rooms] For Social Networking, Chat Room Services For Social Networking, Providing On Line Chat Rooms For Social Networking, On Line Transmission Of Electronic Publications, Messaging Services, Unified Messaging Services, Ums (Unified Messaging Service), Virtual Chat Rooms Established Via Text Messaging, Vide...
[Class : 9] Web Application; Office And Business Applications; Downloadable Mobile Applications For The Management Of Information; Downloadable Mobile Applications For The Management Of Data
View +347 more Brands for Morepen Laboratories Limited.
Charges
30 December 2017
Bmw India Financial Services Private Limited
56 Lak
22 December 2017
Bmw India Financial Services Private Limited
29 Lak
29 November 2017
Daimler Financial Services India Private Limited
54 Lak
11 October 2017
Bmw India Financial Services Private Limited
18 Lak
11 October 2017
Bmw India Financial Services Private Limited
18 Lak
06 October 2017
Bmw India Financial Services Private Limited
29 Lak
22 August 2017
Bmw India Financial Services Private Limited
42 Lak
29 April 2017
Daimler Financial Services India Private Limited
31 Lak
24 April 2017
Punjab National Bank
6 Lak
16 September 2016
Bmw India Financial Services Private Limited
13 Lak
10 February 2016
Punjab National Bank
59 Lak
28 April 2015
Punjab National Bank
6 Lak
27 February 2012
The Karur Vysya Bank Limited
9 Lak
10 February 2012
Export-import Bank Of India
30 Crore
10 February 2012
Uco Bank
46 Crore
10 February 2012
The Karur Vysya Bank Limited
11 Crore
10 February 2012
The Oriental Insurance Company Limited
1 Crore
10 January 2003
The Saraswat Co-op. Bank Limited
50 Lak
08 January 2003
Sicom Limited
15 Crore
08 January 2003
Sicom Limited
15 Crore
23 August 2002
The Karur Vysya Bank Limited
15 Crore
24 July 2002
Industrial Investment Bank Of India Limited
10 Crore
22 June 2002
Sbi Commercial And International Bank Limited
10 Crore
22 June 2002
Sbi Commercial And International Bank Limited
10 Crore
18 January 2002
Uco Bank
50 Crore
18 December 2001
Uti Bank Limited
18 Crore
06 December 2001
Ge Capital Services India
15 Crore
12 October 2001
Export Import Bank Of India
20 Crore
19 September 2001
Indusind Bank Limited
25 Crore
27 July 2001
Bnp Paribas
17 Crore
28 May 2001
Sbi Commercial And International Bank Limited
5 Crore
20 April 2001
Industrial Development Bank Of India
40 Crore
14 March 2001
Export Import Bank Of India
10 Crore
14 March 2001
Export Import Bank Of India
5 Crore
01 February 2001
Sicom Limited
5 Crore
09 January 2001
Industrial Development Bank Of India
25 Crore
27 December 2000
State Bank Of Patiala
10 Crore
16 December 1999
Industrial Investment Bank Of India Limited
20 Crore
30 April 1999
The Icici Limited
5 Crore
16 January 1999
The Icici Limited
1,375 Crore
17 September 1998
Sicom Limited
5 Crore
17 July 1998
The Icici Bank Limited
6 Crore
09 March 1998
The Icici Limited
4 Crore
09 December 1997
Industrial Development Bank Of India
11 Crore
31 March 1997
The Icici Limited
5 Crore
12 March 1997
Industrial Development Bank Of India
5 Crore
23 January 1996
The Cici Banking Corporation Limited
2 Crore
12 May 2016
Bmw India Financial Services Private Limited
7 Lak
24 September 2001
Abu Dhabi Commercial Bank Limited
10 Crore
08 October 1996
State Bank Of India
90 Lak
08 October 1996
State Bank Of India
39 Lak
08 October 1996
State Bank Of India
90 Lak
08 October 1996
State Bank Of India
95 Lak
08 October 1996
State Bank Of India
3 Crore
16 August 2010
The Karur Vysya Bank Ltd
10 Lak
16 September 2010
The Karur Vysya Bank Ltd
9 Lak
06 January 2010
The Karur Vysya Bank Limited
7 Lak
27 April 2002
United Bank Of India
15 Crore
17 April 2000
State Bank Of India
10 Crore
30 July 2001
Bank Of Bahrain And Kuwait B.s.c
12 Crore
07 April 2003
Dombivli Nagri Sahakari Bank Limited
3 Crore
27 April 2002
Bank Of India
30 Crore
25 January 2002
The United Western Bank Limited
10 Crore
30 December 1998
Industrial Finance Corporation Of India Ltd.
10 Crore
16 August 1999
Industrial Finance Corporation Of India Limited
15 Crore
31 July 2001
Hdfc Bank Limited
10 Crore
25 September 2001
Hdfc Bank Limited
8 Crore
27 August 2001
The South Indian Bank Limited
10 Crore
17 June 2002
Lord Krishna Bank Limited
10 Crore
30 June 2001
State Bank Of Bikaner & Jaipur
12 Crore
12 September 2002
Dena Bank
25 Crore
28 May 2002
Bank Of Baroda
25 Crore
28 January 2003
Bank Of Baroda
8 Crore
18 January 2002
Bank Of Baroda
20 Crore
21 December 2001
Oriental Bank Of Commerce
20 Crore
21 December 2001
Oriental Bank Of Commerce
15 Crore
30 December 2000
The Bank Of Nova Scotia(bns)
40 Crore
30 December 2000
The Bank Of Nova Scotia (bns)
40 Crore
05 March 2003
The Dhanlakshmi Bank Limited
5 Crore
23 October 2001
State Bank Of Mysore
15 Crore
27 November 2002
Canara Bank
50 Crore
31 May 2002
The State Bank Of Travancore
30 Crore
16 March 1998
Punjab National Bank
23 Crore
26 November 2002
Punjab National Bank
3 Crore
12 September 2001
Punjab National Bank
49 Crore
24 December 2002
Punjab National Bank
10 Crore
17 January 2000
Punjab National Bank
93 Crore
21 June 2002
Societe Generale
20 Crore
01 February 2000
The Lakshmi Vilas Bank Limited
5 Crore
05 December 1996
Small Industries Development Bank Of India
3 Crore
04 February 2002
Centuran Bank Limited
3 Crore
06 December 2001
Ge Capital Services India
15 Crore
11 February 2021
Uco Bank
67 Lak
11 December 2020
Punjab National Bank
24 Lak
28 August 2023
Others
0
25 October 2022
Others
0
09 November 2022
Others
0
29 April 2017
Others
0
26 April 2022
Others
0
09 March 2022
Others
0
11 December 2020
Others
0
18 January 2002
Uco Bank
0
10 February 2012
Uco Bank
0
22 December 2021
Others
0
22 December 2017
Others
0
28 September 2021
Others
0
19 September 2001
Indusind Bank Limited
0
10 February 2016
Punjab National Bank
0
28 April 2015
Punjab National Bank
0
26 August 2021
Others
0
11 October 2017
Others
0
24 April 2017
Others
0
12 May 2016
Others
0
06 October 2017
Others
0
11 October 2017
Others
0
11 February 2021
Uco Bank
0
22 August 2017
Others
0
30 December 2017
Others
0
16 September 2016
Others
0
06 January 2010
The Karur Vysya Bank Limited
0
16 September 2010
The Karur Vysya Bank Ltd
0
10 February 2012
The Oriental Insurance Company Limited
0
10 February 2012
The Karur Vysya Bank Limited
0
27 February 2012
The Karur Vysya Bank Limited
0
06 December 2001
Ge Capital Services India
0
17 June 2002
Lord Krishna Bank Limited
0
21 December 2001
Oriental Bank Of Commerce
0
30 June 2001
State Bank Of Bikaner & Jaipur
0
27 August 2001
The South Indian Bank Limited
0
27 April 2002
Bank Of India
0
22 June 2002
Sbi Commercial And International Bank Limited
0
30 December 2000
The Bank Of Nova Scotia (bns)
0
31 May 2002
The State Bank Of Travancore
0
23 August 2002
The Karur Vysya Bank Limited
0
10 January 2003
The Saraswat Co-op. Bank Limited
0
24 December 2002
Punjab National Bank
0
21 June 2002
Societe Generale
0
25 September 2001
Hdfc Bank Limited
0
30 April 1999
The Icici Limited
0
16 January 1999
The Icici Limited
0
25 January 2002
The United Western Bank Limited
0
18 January 2002
Bank Of Baroda
0
14 March 2001
Export Import Bank Of India
0
06 December 2001
Ge Capital Services India
0
12 September 2001
Punjab National Bank
0
30 July 2001
Bank Of Bahrain And Kuwait B.s.c
0
27 July 2001
Bnp Paribas
0
28 May 2001
Sbi Commercial And International Bank Limited
0
17 April 2000
State Bank Of India
0
16 December 1999
Industrial Investment Bank Of India Limited
0
16 August 1999
Industrial Finance Corporation Of India Limited
0
01 February 2000
The Lakshmi Vilas Bank Limited
0
17 September 1998
Sicom Limited
0
09 December 1997
Industrial Development Bank Of India
0
12 March 1997
Industrial Development Bank Of India
0
23 January 1996
The Cici Banking Corporation Limited
0
17 January 2000
Punjab National Bank
0
05 December 1996
Small Industries Development Bank Of India
0
21 December 2001
Oriental Bank Of Commerce
0
07 April 2003
Dombivli Nagri Sahakari Bank Limited
0
08 October 1996
State Bank Of India
0
08 October 1996
State Bank Of India
0
22 June 2002
Sbi Commercial And International Bank Limited
0
08 January 2003
Sicom Limited
0
29 November 2017
Others
0
08 October 1996
State Bank Of India
0
10 February 2012
Export-import Bank Of India
0
12 September 2002
Dena Bank
0
27 November 2002
Canara Bank
0
04 February 2002
Centuran Bank Limited
0
27 April 2002
United Bank Of India
0
05 March 2003
The Dhanlakshmi Bank Limited
0
08 January 2003
Sicom Limited
0
30 December 2000
The Bank Of Nova Scotia(bns)
0
18 December 2001
Uti Bank Limited
0
24 July 2002
Industrial Investment Bank Of India Limited
0
28 May 2002
Bank Of Baroda
0
12 October 2001
Export Import Bank Of India
0
17 July 1998
The Icici Bank Limited
0
09 March 1998
The Icici Limited
0
20 April 2001
Industrial Development Bank Of India
0
14 March 2001
Export Import Bank Of India
0
01 February 2001
Sicom Limited
0
09 January 2001
Industrial Development Bank Of India
0
27 December 2000
State Bank Of Patiala
0
24 September 2001
Abu Dhabi Commercial Bank Limited
0
31 July 2001
Hdfc Bank Limited
0
31 March 1997
The Icici Limited
0
30 December 1998
Industrial Finance Corporation Of India Ltd.
0
16 March 1998
Punjab National Bank
0
26 November 2002
Punjab National Bank
0
28 January 2003
Bank Of Baroda
0
23 October 2001
State Bank Of Mysore
0
08 October 1996
State Bank Of India
0
08 October 1996
State Bank Of India
0
16 August 2010
The Karur Vysya Bank Ltd
0
28 August 2023
Others
0
25 October 2022
Others
0
09 November 2022
Others
0
29 April 2017
Others
0
26 April 2022
Others
0
09 March 2022
Others
0
11 December 2020
Others
0
18 January 2002
Uco Bank
0
10 February 2012
Uco Bank
0
22 December 2021
Others
0
22 December 2017
Others
0
28 September 2021
Others
0
19 September 2001
Indusind Bank Limited
0
10 February 2016
Punjab National Bank
0
28 April 2015
Punjab National Bank
0
26 August 2021
Others
0
11 October 2017
Others
0
24 April 2017
Others
0
12 May 2016
Others
0
06 October 2017
Others
0
11 October 2017
Others
0
11 February 2021
Uco Bank
0
22 August 2017
Others
0
30 December 2017
Others
0
16 September 2016
Others
0
06 January 2010
The Karur Vysya Bank Limited
0
16 September 2010
The Karur Vysya Bank Ltd
0
10 February 2012
The Oriental Insurance Company Limited
0
10 February 2012
The Karur Vysya Bank Limited
0
27 February 2012
The Karur Vysya Bank Limited
0
06 December 2001
Ge Capital Services India
0
17 June 2002
Lord Krishna Bank Limited
0
21 December 2001
Oriental Bank Of Commerce
0
30 June 2001
State Bank Of Bikaner & Jaipur
0
27 August 2001
The South Indian Bank Limited
0
27 April 2002
Bank Of India
0
22 June 2002
Sbi Commercial And International Bank Limited
0
30 December 2000
The Bank Of Nova Scotia (bns)
0
31 May 2002
The State Bank Of Travancore
0
23 August 2002
The Karur Vysya Bank Limited
0
10 January 2003
The Saraswat Co-op. Bank Limited
0
24 December 2002
Punjab National Bank
0
21 June 2002
Societe Generale
0
25 September 2001
Hdfc Bank Limited
0
30 April 1999
The Icici Limited
0
16 January 1999
The Icici Limited
0
25 January 2002
The United Western Bank Limited
0
18 January 2002
Bank Of Baroda
0
14 March 2001
Export Import Bank Of India
0
06 December 2001
Ge Capital Services India
0
12 September 2001
Punjab National Bank
0
30 July 2001
Bank Of Bahrain And Kuwait B.s.c
0
27 July 2001
Bnp Paribas
0
28 May 2001
Sbi Commercial And International Bank Limited
0
17 April 2000
State Bank Of India
0
16 December 1999
Industrial Investment Bank Of India Limited
0
16 August 1999
Industrial Finance Corporation Of India Limited
0
01 February 2000
The Lakshmi Vilas Bank Limited
0
17 September 1998
Sicom Limited
0
09 December 1997
Industrial Development Bank Of India
0
12 March 1997
Industrial Development Bank Of India
0
23 January 1996
The Cici Banking Corporation Limited
0
17 January 2000
Punjab National Bank
0
05 December 1996
Small Industries Development Bank Of India
0
21 December 2001
Oriental Bank Of Commerce
0
07 April 2003
Dombivli Nagri Sahakari Bank Limited
0
08 October 1996
State Bank Of India
0
08 October 1996
State Bank Of India
0
22 June 2002
Sbi Commercial And International Bank Limited
0
08 January 2003
Sicom Limited
0
29 November 2017
Others
0
08 October 1996
State Bank Of India
0
10 February 2012
Export-import Bank Of India
0
12 September 2002
Dena Bank
0
27 November 2002
Canara Bank
0
04 February 2002
Centuran Bank Limited
0
27 April 2002
United Bank Of India
0
05 March 2003
The Dhanlakshmi Bank Limited
0
08 January 2003
Sicom Limited
0
30 December 2000
The Bank Of Nova Scotia(bns)
0
18 December 2001
Uti Bank Limited
0
24 July 2002
Industrial Investment Bank Of India Limited
0
28 May 2002
Bank Of Baroda
0
12 October 2001
Export Import Bank Of India
0
17 July 1998
The Icici Bank Limited
0
09 March 1998
The Icici Limited
0
20 April 2001
Industrial Development Bank Of India
0
14 March 2001
Export Import Bank Of India
0
01 February 2001
Sicom Limited
0
09 January 2001
Industrial Development Bank Of India
0
27 December 2000
State Bank Of Patiala
0
24 September 2001
Abu Dhabi Commercial Bank Limited
0
31 July 2001
Hdfc Bank Limited
0
31 March 1997
The Icici Limited
0
30 December 1998
Industrial Finance Corporation Of India Ltd.
0
16 March 1998
Punjab National Bank
0
26 November 2002
Punjab National Bank
0
28 January 2003
Bank Of Baroda
0
23 October 2001
State Bank Of Mysore
0
08 October 1996
State Bank Of India
0
08 October 1996
State Bank Of India
0
16 August 2010
The Karur Vysya Bank Ltd
0
Documents
Form AOC-4(XBRL)-02082021-signed
Form CHG-1-01012021_signed
Instrument(s) of creation or modification of charge;-31122020
CERTIFICATE OF REGISTRATION OF CHARGE-20201231
Form AOC-4(XBRL)-01012021-signed
XBRL document in respect Consolidated financial statement-31122020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-31122020
Statement of subsidiaries as per section 129-Form AOC-1 (To be attached in respect of Foreign subsidiaries)-31122020
Form MGT-14-02112020-signed
CERTIFICATE OF REGISTRATION OF THE SPECIAL RESOLUTION CONFIRMING ALTERATION OF OBJECT CLAUSE(S)-20201102
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-31102020
Altered articles of association-31102020
Altered memorandum of association-31102020
Optional Attachment-(2)-31102020
Optional Attachment-(1)-31102020
Form SH-7-28102020-signed
Optional Attachment-(1)-18102020
Form DIR-12-18102020_signed
Copy of the resolution for alteration of capital;-17102020
Optional Attachment-(1)-17102020
Altered memorandum of assciation;-17102020
Form MGT-15-15102020_signed
Form MGT-14-01102020_signed
Form INC-28-21072020-signed
Form DIR-12-06072020_signed
Declaration of the appointee director, Managing director, in Form No. DIR-2;-05072020
Optional Attachment-(1)-05072020
Optional Attachment-(2)-05072020
Form DPT-3-30062020-signed
Form CHG-4-28012020_signed
